205 related articles for article (PubMed ID: 24319226)
1. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes.
Saunthararajah Y
Hematology Am Soc Hematol Educ Program; 2013; 2013():511-21. PubMed ID: 24319226
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
[TBL] [Abstract][Full Text] [Related]
3. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
[TBL] [Abstract][Full Text] [Related]
4. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Tohyama K
Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
[TBL] [Abstract][Full Text] [Related]
5. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
8. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).
Silverman LR
Oncologist; 2001; 6 Suppl 5():8-14. PubMed ID: 11700387
[TBL] [Abstract][Full Text] [Related]
9. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
[TBL] [Abstract][Full Text] [Related]
10. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Wu L; Li X; Xu F; Chang C; He Q; Zhang Z; Zhang Y
Ann Hematol; 2012 Oct; 91(10):1547-54. PubMed ID: 22580751
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL
J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
[TBL] [Abstract][Full Text] [Related]
15. Decitabine.
Hackanson B; Daskalakis M
Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Yee KW; Jabbour E; Kantarjian HM; Giles FJ
Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
[TBL] [Abstract][Full Text] [Related]
17. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
[TBL] [Abstract][Full Text] [Related]
19. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
[TBL] [Abstract][Full Text] [Related]
20. The role of decitabine in the treatment of myelodysplastic syndromes.
Atallah E; Kantarjian H; Garcia-Manero G
Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
